TECKRO
21.7.2020 15:08:14 CEST | Business Wire | Press release
Teckro celebrates its fifth anniversary as the company expands its executive team to support growing demand due to COVID-19.
The revolutionary Teckro digital engagement platform supports a number of high profile COVID-19 clinical trials for major pharmaceutical companies. Teckro is now looking to expand its global profile and take the company to the next level of growth.
“Five years is an important milestone that illustrates the staying power of our vision,” says CEO Gary Hughes. “I am proud of our team and their dedication to making Teckro technology synonymous with clinical trials. As we look forward, it is important that we bring in the right people who can help accelerate our growth. This is why I am delighted to announce Amanda Buckley as the newest member of our executive team.”
Amanda brings more than 25 years of software experience, including as general manager of Veeva Systems in Europe where she was responsible for all field operations and strategy in the region. In her role as Teckro COO, Amanda will work with Gary and the senior leadership team to scale world-class operations.
Amanda says: “I’m delighted to be part of the Teckro team at such an interesting time for clinical trials. As the industry responds to the wake-up call delivered by the pandemic, it is a great opportunity for solutions like Teckro to improve efficiency and reduce friction in clinical trials.”
Also today, new industry research finds that investigative site staff most often rely on paper and desktop computers to reference protocol instructions. The research, conducted by the Tufts Center for the Study of Drug Development (CSDD) in collaboration with Teckro, gathered responses from 228 investigative site staff on how and when they interact with the clinical trial protocol. The findings are published in a new report: Tufts CSDD - Teckro 2020 Study on Investigative Site Protocol Administration Referencing Practices . Read the press release for more details.
About Teckro
Teckro clinical trial software connects all study stakeholders with a digital engagement platform. Global pharmaceuticals and emerging biotechnology companies alike rely on Teckro for all trial phases and therapeutic areas. Teckro is used at more than 14,000 active research sites around the world. Headquartered in Limerick, Ireland, Teckro has locations across Europe and the United States and employs more than 120 staff.
More Information:
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005569/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hyper Brings its Latest Range of Power, Connectivity and MacBook Accessories to IFA 20264.9.2026 07:00:00 CEST | Press release
The latest additions to Hyper's portfolio make everyday mobile setups more personal, portable and productive across work, creating and travel Messe Berlin – IFA 2026 (Hall 5.2, Stand 179) – Hyper®, an innovator of mobile accessories for Apple users, creators and mobile professionals, will showcase its latest lineup at IFA 2026, designed to make everyday mobile setups more personal, portable and productive across work, creating and travel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903870923/en/ Discover Hyper's latest MacBook accessories, power and connectivity solutions debuting at IFA 2026 Building on essential MacBook Neo accessories, the range expands across portable charging, privacy, workspace connectivity and carry solutions, led by HyperJuice Flex, Hyper’s colourful and accessible collection designed to make everyday power more portable and personal. “At IFA, we’re introducing an everyday ecosystem built aroun
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 22:30:00 CEST | Press release
ReActiv8® Restorative Neurostimulation™ treatment group showed sustained improvements in measures of disability, pain and quality of life from the one-year to the two-year timepoints.83% of control group patients elected to cross over and receive ReActiv8 therapy after the one-year assessment.After one year of ReActiv8 therapy, the outcomes in the crossover group were indistinguishable from the treatment group at the same time point, confirming the effect is reproducible, robust, and not cohort specific. Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
Lenovo Advances Hybrid AI Across New Personal and Enterprise Technology3.9.2026 18:00:00 CEST | Press release
Lenovo announces expanded Lenovo and Motorola Qira experiences and availability, new Yoga, Idea, Think, and Motorola devices, and concepts that explore the next era of more personal, connected technology. Today at Lenovo™ Innovation World during IFA 2026, Lenovo unveiled a new portfolio of personal and enterprise technology, showing how its Hybrid AI strategy is moving from vision to practical experiences across devices, infrastructure, services, and the everyday moments that connect them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903555953/en/ Lenovo Innovation World at IFA 2026 The announcements bring together Lenovo’s “one personal AI, multiple devices” approach with enterprise technology that helps organizations turn data into insights and value. They span personal AI across PCs, smartphones, tablets, and wearables; creator and consumer devices that adapt to different ways of working and expressing ideas; and bus
Bahrain Signs its Participation Contract for Expo 2030 Riyadh3.9.2026 17:45:00 CEST | Press release
The Kingdom of Bahrain has signed its Participation Contract for Expo 2030 Riyadh, marking a new phase in preparations for its participation in the World Expo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903144412/en/ His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President of the Bahrain Authority for Culture and Antiquities, and Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, at the ceremony. The agreement provides the formal framework for Bahrain’s participation in Expo 2030 Riyadh, enabling preparations to advance across the key organizational and operational aspects of its presence throughout the six-month event, including the development of its pavilion, programmes and visitor experiences. The Participation Contract was signed in Bahrain by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, on behalf of Expo 2030 Riyadh, and His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom